Cocrystal Pharma, Inc.: management transactions · United States · SEC (Form 4)

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (ticker: COCP) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. It is a clinical-stage biotech focused on discovering and developing broad-spectrum antiviral drug candidates designed to address important unmet medical needs. The company’s business model is centered on research and development, intellectual property creation, preclinical and clinical validation, and, ultimately, potential partnering, licensing, or commercialization of antiviral assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai)) The company was built around a technology-led antiviral strategy. According to recent SEC filings, Cocrystal is a Delaware corporation and its business address is in Bothell, Washington, placing it in one of the key life-science clusters of the Pacific Northwest. The latest available SEC materials describe Cocrystal as a clinical-stage biopharmaceutical company developing novel technologies and approaches intended to create first-in-class or best-in-class antiviral drug candidates. Since inception, its activities have mainly consisted of acquiring product and technology rights, raising capital, and performing research and development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai)) From a business-line perspective, Cocrystal is highly focused rather than diversified. Its core competency is viral replication inhibition, and its pipeline has been aimed at difficult-to-treat viral diseases. Public disclosures reference programs addressing influenza, viral gastroenteritis, COVID-19, and hepatitis. This narrow strategic focus can be attractive for investors looking for asymmetric upside from clinical progress, but it also means the equity case depends heavily on a limited number of assets and on the company’s ability to secure ongoing funding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1412486/000164117225027246/ex99-1.htm?utm_source=openai)) In competitive terms, Cocrystal operates in a crowded antiviral landscape that includes global pharmaceutical companies, specialized biotech developers, and alternative therapeutic approaches such as vaccines, antibodies, and symptom-management treatments. The company’s differentiation lies in its scientific approach to targeting viral replication mechanisms, with the goal of delivering broad-spectrum antiviral options. For investors, this translates into a classic small-cap biotech risk profile: meaningful scientific optionality, but also elevated execution risk, clinical uncertainty, and dilution risk if capital markets remain the main funding source. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai)) Geographically, Cocrystal’s footprint is predominantly U.S.-centric, with operations and regulatory presence anchored in Bothell, Washington, and with equity market visibility through NASDAQ under the symbol COCP. Recent developments show that the company has continued to rely on capital markets to fund its programs, including a registered direct financing announced in September 2025, as well as subsequent operational updates and quarterly reporting in 2026. These disclosures reinforce that Cocrystal remains an investment-stage biotech, where cash runway, pipeline progress, and clinical milestones are the key drivers to watch. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-014819-index.htm?utm_source=openai))